AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
References
Sources used in this report
SEC APISEC company tickers exchange dataset2026-05-14 · Ticker, issuer name, exchange and CIK confirmation.SEC APISEC submissions for AEON2026-05-14 · Issuer identity, SIC, fiscal year end and recent filing sequence.SEC XBRL APISEC companyfacts for AEON2026-05-14 · Tagged cash, assets, liabilities, deficit, loss, SG&A and R&D facts.SEC annual filingAEON fiscal 2025 Form 10-K2026-03-30 · Business description, ABP-450, Daewoong agreement, financial statements, going concern, risk factors and subsequent events.SEC quarterly filingAEON Q3 2025 Form 10-Q2025-11-14 · Interim cash, liabilities, operating loss and liquidity context.Company Form 8-K exhibitFY2025 results and ABP-450 update release2026-03-30 · FDA BPD Type 2a feedback, analytical-similarity update, financing, note exchange and runway.Company Form 8-K exhibitNYSE American continued-listing notice release2026-04-03 · Continued-listing deficiency, stockholders' deficit, plan period and trading indicator.Company Form 8-K exhibitFDA meeting and shareholder approval release2026-01-21 · BPD Type 2a meeting occurrence, shareholder approval, PIPE and Daewoong note exchange.Company Form 8-K exhibitJanuary 2026 investor presentation2026-01-12 · Development timeline and capital-structure context.Proxy filingAEON 2026 proxy statement2026-04-29 · Shares outstanding, board nominees, annual meeting, beneficial ownership and governance context.Registration statementAEON 2026 Form S-32026-02-09 · Resale registration and dilution context.Peer annual filingEvolus fiscal 2025 Form 10-K2026-03-03 · Jeuveau commercialization and same Daewoong toxin context.Peer annual filingAbbVie fiscal 2025 Form 10-K2026-02-20 · BOTOX Therapeutic and BOTOX Cosmetic descriptions and product revenue scale.